In patients with treatment-resistant depression, esketamine nasal spray plus an SSRI or SNRI was superior to extended-release quetiapine plus an SSRI or SNRI with respect to remission at week 8.

The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, Spravato (esketamine), as a standalone therapy for adults with treatment-resistant depression. Spravato ...

A nasal spray containing a ketamine derivative appears to beat one of the standard drugs used for people with difficult-to-treat depression, a new clinical trial has found.

Nasal esketamine spray is more effective than an extended-release antipsychotic, when both are taken in combination with SSRIs and SNRIs, in treatment-resistant depression, a study found.

The nasal spray, from Janssen Pharmaceuticals, is sold under the name Spravato and was approved by the Food and Drug Administration for treatment-resistant depression in 2019.

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive ...

HOUSTON – Treatment-resistant depression may affect as many as a third of people with the disorder. That means medications don’t work and patients have difficulty enjoying life and being ...

The FDA approval of the nasal spray allows the medication to be covered by insurance, whereas earlier IV treatments were not. “It started out as an IV form of medication. You would get an ...

Start with a nasal spray or nose drops so that your child can get used to the feeling of the insides of their nose being wet. When your child gets used to the nasal spray, move up to saline rinses.